Form 4: Amneal Pharmaceuticals Executive Vice President Andrew Boyer Reports Stock Transactions
SEC Form 4 Filing
Executive Vice President Andrew Boyer of Amneal Pharmaceuticals reports the vesting of restricted stock units and subsequent stock transactions.
Summary
- On February 27, 2024, Andrew Boyer, Executive Vice President of Amneal Pharmaceuticals, reported transactions involving Class A Common Stock.
- 31,663 shares were acquired upon the vesting of restricted stock units.
- 16,556 shares were disposed of to satisfy tax withholding obligations at a price of $5.71 per share.
- Following these transactions, Boyer directly owns 259,846 shares of Class A Common Stock.
- The restricted stock units were granted on February 27, 2020, and vest in four equal annual installments.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard reporting of stock transactions related to executive compensation.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies.
Key Dates
| Date | Description |
|---|---|
| 02/27/2020 | Date the reporting person was granted 126,649 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. |
| 02/27/2024 | Date of stock transactions: vesting of restricted stock units and shares withheld for tax obligations. |
| 02/29/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.